MA57504B1 - Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
MA57504B1
MA57504B1 MA57504A MA57504A MA57504B1 MA 57504 B1 MA57504 B1 MA 57504B1 MA 57504 A MA57504 A MA 57504A MA 57504 A MA57504 A MA 57504A MA 57504 B1 MA57504 B1 MA 57504B1
Authority
MA
Morocco
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
MA57504A
Other languages
English (en)
Inventor
Alisha B Arrigo
Derrick Juengst
Khalid Shah
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA57504B1 publication Critical patent/MA57504B1/fr

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une nouvelle forme cristalline de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)- l'invention concerne le 3-hydroxypyrrolidine-1-carboxamide, des compositions pharmaceutiques contenant ladite forme cristalline et l'utilisation de ladite forme cristalline dans le traitement de la douleur, du cancer, de l'inflammation, d'une maladie neurodégénérative ou d'une infection à trypanosoma cruzi. Dans certains modes de réalisation, la nouvelle forme cristalline comprend un polymorphe stable de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a hydrogénosulfate de ]pyrimidine-3-yl)-3-hydroxypyrrolidine-1-carboxamide.
MA57504A 2014-11-16 2015-11-16 Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide MA57504B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080374P 2014-11-16 2014-11-16

Publications (1)

Publication Number Publication Date
MA57504B1 true MA57504B1 (fr) 2023-03-31

Family

ID=85793880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57504A MA57504B1 (fr) 2014-11-16 2015-11-16 Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Country Status (1)

Country Link
MA (1) MA57504B1 (fr)

Similar Documents

Publication Publication Date Title
PH12021550809A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA50817B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
EA201492082A1 (ru) Кристаллические формы ингибитора тирозинкиназы брутона
TN2018000335A1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA34926B1 (fr) Composition effervescente sous forme solide utilisable dans des applications vaginales pour le traitement d'infections vaginales
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
MX2024010140A (es) Nuevos metodos.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2021002322A (es) Nuevos metodos.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения
FR3084254B1 (fr) Derives deuteres du lanifibranor
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
AR062114A1 (es) Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA57504B1 (fr) Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide